Drug Profile
Sitravatinib - Mirati Therapeutics
Alternative Names: MG-516; MG91516; MGCD-0516; MGCD-516; Sitravatinib-malate; Sitravatinib-malate-Mirati-TherapeuticsLatest Information Update: 22 Jan 2020
Price :
$50
*
At a glance
- Originator MethylGene
- Developer BeiGene; Bristol-Myers Squibb; Cancer Research UK; Columbia University; Mirati Therapeutics; University Health Network; University of Birmingham
- Class Antineoplastics; Cyclopropanes; Pyridines; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Eph family receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c met inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Proto-oncogene protein c-mer inhibitors; Receptor protein-tyrosine kinase antagonists; RON protein inhibitors; TIE 2 receptor antagonists; Tropomyosin-related kinase antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Liposarcoma; Renal cell carcinoma; Soft tissue sarcoma; Urogenital cancer
- Phase I/II Gastric cancer; Liver cancer
- Phase I Cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
Most Recent Events
- 23 Dec 2019 Phase-I clinical trials in Cancer (In volunteers) in Netherlands (PO)
- 13 Dec 2019 Efficacy and adverse events data from a phase Ib trial in Solid tumours presented at the 44th European Society for Medical Oncology Congress (ESMO-2019)
- 22 Nov 2019 Interim efficacy data from a phase I SNOW trial in Squamous cell cancer presented at the 34th Annual Meeting of The Society of Immunotherapy of Cancer (STIC-2019)[700297283]